JP7259169B2 - Differentiation method of skin condition - Google Patents
Differentiation method of skin condition Download PDFInfo
- Publication number
- JP7259169B2 JP7259169B2 JP2018172460A JP2018172460A JP7259169B2 JP 7259169 B2 JP7259169 B2 JP 7259169B2 JP 2018172460 A JP2018172460 A JP 2018172460A JP 2018172460 A JP2018172460 A JP 2018172460A JP 7259169 B2 JP7259169 B2 JP 7259169B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- myokine
- skin condition
- blood
- estimated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 23
- 230000004069 differentiation Effects 0.000 title description 8
- 210000004369 blood Anatomy 0.000 claims description 45
- 239000008280 blood Substances 0.000 claims description 45
- 230000037303 wrinkles Effects 0.000 claims description 26
- 238000012850 discrimination method Methods 0.000 claims description 25
- 230000019612 pigmentation Effects 0.000 claims description 22
- -1 INF-γ Proteins 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 7
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 claims description 5
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 claims description 5
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical group NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 claims description 4
- 102000011690 Adiponectin Human genes 0.000 claims description 4
- 108010076365 Adiponectin Proteins 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 4
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims description 4
- 102000004225 Cathepsin B Human genes 0.000 claims description 4
- 108090000712 Cathepsin B Proteins 0.000 claims description 4
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 claims description 4
- 102100020997 Fractalkine Human genes 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 4
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 claims description 4
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 4
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102000003812 Interleukin-15 Human genes 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 102000004890 Interleukin-8 Human genes 0.000 claims description 4
- 101800001026 Irisin Proteins 0.000 claims description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 4
- 102000034655 MIF Human genes 0.000 claims description 4
- 108060004872 MIF Proteins 0.000 claims description 4
- 101710091439 Major capsid protein 1 Proteins 0.000 claims description 4
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical group OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 109
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 36
- 238000005259 measurement Methods 0.000 description 22
- 210000000434 stratum corneum Anatomy 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 230000036572 transepidermal water loss Effects 0.000 description 5
- 239000011148 porous material Substances 0.000 description 4
- 150000004032 porphyrins Chemical class 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 238000009223 counseling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000003702 image correction Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Description
本発明は、血中マイオカイン濃度を指標として肌状態を鑑別する方法に関する。 TECHNICAL FIELD The present invention relates to a method for discriminating skin conditions using blood myokine concentration as an index.
素肌を美しく保ったり化粧を施したりするために、スキンケアやメークアップの方法を検討したり、化粧品を選択したりするに際して、肌の表面や内部の状態、例えば肌のハリ・弾力、色、角層の状態、老化度、キメ、シワ、毛穴、色素沈着等を的確に把握することは重要である。
これまでに、皮膚から得たレプリカ画像や皮膚の拡大写真を評価材料として、これらに画像処理を施して得た情報を利用して、シワやキメを鑑別する技術が開示されている（特許文献１、２）。
また、皮膚を直接的に計測して、その内部構造情報を得て、肌の状態の鑑別に供する方法も開発されている。例えば、厚みのある生体試料を非侵襲的に観察することを可能とした共焦点レーザー顕微鏡により得た画像等に基づいて、肌の状態を鑑別する方法が注目されている（特許文献３～６）。
In order to keep the bare skin beautiful and apply makeup, when considering skin care and makeup methods and selecting cosmetics, the surface and internal conditions of the skin, such as the firmness, elasticity, color, and corners of the skin. It is important to accurately grasp the state of the layer, degree of aging, texture, wrinkles, pores, pigmentation, and the like.
So far, techniques have been disclosed for discriminating wrinkles and texture using replica images obtained from skin and enlarged photographs of skin as evaluation materials and using information obtained by performing image processing on these (Patent Document 1, 2).
Methods have also been developed for directly measuring the skin to obtain information on its internal structure and using the information to identify the condition of the skin. For example, attention has been paid to a method for differentiating skin conditions based on images obtained by a confocal laser microscope that enables noninvasive observation of thick biological samples (Patent Documents 3 to 6). ).
本発明は、より簡便かつ高精度に、肌状態を推定することができる、肌状態の鑑別法を提供することを目的とする。 SUMMARY OF THE INVENTION An object of the present invention is to provide a skin condition discrimination method that can estimate the skin condition more simply and accurately.
本発明者等は上記課題を解決するために鋭意研究を行った結果、筋肉から分泌されるサイトカインであるマイオカイン（Ｍｙｏｋｉｎｅ）に着目し、血液中のマイオカイン濃度が、種々の肌状態の良し悪しと相関することを見出した。そして、血中マイオカイン濃度を指標として肌状態を推定し、その推定結果に基づいて肌の状態の良し悪しを鑑別することができることに想到し、本発明を完成するに至った。 As a result of intensive research to solve the above problems, the present inventors have focused on myokine, which is a cytokine secreted from muscles, and found that the concentration of myokine in the blood affects various skin conditions. found to be correlated. Then, the inventors have come up with the idea that the skin condition can be estimated using the blood myokine concentration as an index, and based on the estimation results, it is possible to distinguish between good and bad skin conditions, leading to the completion of the present invention.
すなわち、本発明は以下の通りである。
[１]血中マイオカイン濃度を指標として肌状態を推定することを特徴とする、肌状態の鑑別法。
[２]血中マイオカイン濃度が高い場合に肌状態が良いと推定する、[１]に記載の鑑別法。[３]前記マイオカインが、カテプシンＢ、ＩＬ－４、ＩＬ－６、ＩＬ－８、ＩＬ－１０、ＩＬ－１５、ＬＩＦ、ＣＸ３ＣＬ１、ＧＭ－ＣＳＦ、ＴＮＦ－α、アディポネクチン、ＩＮＦ－γ、及びＢＤＮＦから選択される、[２]に記載の鑑別法。
[４]推定される肌状態が、色素沈着、肌色、肌荒れ、及びハリ・弾力から選択される、[３]に記載の鑑別法。
[５]血中マイオカイン濃度が低い場合に肌状態が良いと推定する、[１]に記載の鑑別法。
[６]前記マイオカインが、イリシン、ＩＬ－７、ＩＬ－１β、ＭＣＰ１、ＣＸＣＬ１、及びＳＰＡＲＣから選択される、[５]に記載の鑑別法。
[７]推定される肌状態が、色素沈着、肌色、肌荒れ、ハリ・弾力から選択される、[６]に記載の鑑別法。
[８]前記マイオカインが、ＭＩＦ、ＣＸＣＬ５、及びＣＸＣＬ６から選択される、[１]に記載の鑑別法。
[９]血中マイオカイン濃度が高い場合に肌荒れの肌状態が良いと推定する、[８]に記載の鑑別法。
[１０]血中マイオカイン濃度が低い場合に、シワ及び色素沈着から選択される肌状態が良いと推定する、[８]に記載の鑑別法。
[１１]前記マイオカインが、ＢＡＩＢＡである、[１]に記載の鑑別法。
[１２]血中マイオカイン濃度が高い場合に色素沈着の肌状態が良いと推定する、[１１]に記載の鑑別法。
[１３]血中マイオカイン濃度が低い場合に、肌荒れの肌状態が良いと推定する、[１１]に記載の鑑別法。
[１４]前記肌状態の推定が、多変量解析によって得られた推定式を用いて行われる、[１]～[１３]のいずれかに記載の鑑別法。
That is, the present invention is as follows.
[1] A skin condition discrimination method characterized by estimating the skin condition using the blood myokine concentration as an index.
[2] The discrimination method according to [1], wherein the skin condition is estimated to be good when the blood myokine concentration is high. [3] the myokine is cathepsin B, IL-4, IL-6, IL-8, IL-10, IL-15, LIF, CX3CL1, GM-CSF, TNF-α, adiponectin, INF-γ, and BDNF The identification method according to [2], which is selected from
[4] The discrimination method according to [3], wherein the estimated skin condition is selected from pigmentation, skin color, rough skin, and firmness/elasticity.
[5] The discrimination method according to [1], wherein the skin condition is estimated to be good when the blood myokine concentration is low.
[6] The method of differentiation according to [5], wherein the myokine is selected from irisin, IL-7, IL-1β, MCP1, CXCL1, and SPARC.
[7] The discrimination method according to [6], wherein the estimated skin condition is selected from pigmentation, skin color, rough skin, firmness/elasticity.
[8] The method of differentiation according to [1], wherein the myokine is selected from MIF, CXCL5, and CXCL6.
[9] The differentiation method according to [8], wherein when the blood myokine concentration is high, the rough skin condition is estimated to be good.
[10] The differentiation method according to [8], wherein when the blood myokine concentration is low, the skin condition selected from wrinkles and pigmentation is estimated to be good.
[11] The identification method according to [1], wherein the myokine is BAIBA.
[12] The differentiation method according to [11], wherein when the blood myokine concentration is high, the pigmentation of the skin is estimated to be good.
[13] The differentiation method according to [11], wherein when the blood myokine concentration is low, it is estimated that the rough skin condition is good.
[14] The discrimination method according to any one of [1] to [13], wherein the skin condition is estimated using an estimation formula obtained by multivariate analysis.
本発明により、簡便かつ高精度に、シワ、色素沈着、肌色、肌荒れ、及びハリ・弾力等の肌状態を鑑別する方法が提供される。これにより、個人に合わせた肌の手入れや化粧方法を検討・選択・決定する際に有用な情報を得ることができ、該情報を肌の手入れや化粧方法に関するカウンセリングにも利用できる。 INDUSTRIAL APPLICABILITY The present invention provides a method for simply and accurately discriminating skin conditions such as wrinkles, pigmentation, skin color, rough skin, and firmness/elasticity. As a result, useful information can be obtained when examining, selecting, and determining skin care and makeup methods suited to the individual, and the information can be used for counseling on skin care and makeup methods.
本発明の肌状態の鑑別法は、血中マイオカイン濃度を指標として肌状態を推定することを特徴とする。
マイオカインは筋肉から分泌されるサイトカインの総称であり、多種見出されている。本発明の鑑別法には、特に限定されないが、カテプシンＢ、ＩＬ－４、ＩＬ－６、ＩＬ－７、ＩＬ－８、ＩＬ－１０、ＩＬ－１５、ＬＩＦ、ＣＸ３ＣＬ１、ＧＭ－ＣＳＦ、ＴＮＦ－α、アディポネクチン、ＩＮＦ－γ、ＢＤＮＦ、ＳＰＡＲＣ、イリシン、ＩＬ－１β、ＭＣＰ１、ＣＸＣＬ１、ＭＩＦ、ＣＸＣＬ５、ＣＸＣＬ６、ＢＡＩＢＡ等を指標として好ましく用いることができる。
The skin condition discrimination method of the present invention is characterized by estimating the skin condition using the blood myokine concentration as an index.
Myokine is a general term for cytokines secreted from muscles, and various types have been found. The differentiation method of the present invention includes, but is not limited to, cathepsin B, IL-4, IL-6, IL-7, IL-8, IL-10, IL-15, LIF, CX3CL1, GM-CSF, TNF- α, adiponectin, INF-γ, BDNF, SPARC, irisin, IL-1β, MCP1, CXCL1, MIF, CXCL5, CXCL6, BAIBA and the like can be preferably used as indicators.
マイオカイン濃度を測定する血液試料としては、全血、血清、血漿等を用いることができ、特に限定されない。
血液中のマイオカイン濃度の測定法は、常法により行うことができる。
Whole blood, serum, plasma, or the like can be used as a blood sample for measuring the myokine concentration, and is not particularly limited.
The myokine concentration in blood can be measured by a conventional method.
後述の実施例に示される通り、特定のマイオカインの血中濃度が高い人では肌状態が良好であり、特定のマイオカインの血中濃度が低い人では肌状態が不良であるという有意な傾向が認められる。さらに、特定のマイオカインの血中濃度の高低と、特定の肌状態の良不良との間にも有意な相関関係が認められる。
本発明の鑑別方法は、これらの相関関係に基づいて、マイオカインの種類によりその血中濃度が高い又は低いかによって、肌状態が良い又は不良であると推定するものであり、かかる推定は例えば予め用意した基準に当てはめて行うことができる。
As shown in the examples below, there was a significant tendency that people with high blood levels of specific myokines had good skin conditions, and people with low blood levels of specific myokines had poor skin conditions. be done. Furthermore, a significant correlation is also observed between the level of specific myokines in the blood and the quality of specific skin conditions.
Based on these correlations, the discrimination method of the present invention estimates that the skin condition is good or bad depending on whether the blood concentration is high or low depending on the type of myokine. It can be performed by applying the prepared standards.
具体的には、カテプシンＢ、ＩＬ－４、ＩＬ－６、ＩＬ－８、ＩＬ－１０、ＩＬ－１５、ＬＩＦ、ＣＸ３ＣＬ１、ＧＭ－ＣＳＦ、ＴＮＦ－α、アディポネクチン、ＩＮＦ－γ、及びＢＤＮＦから選択されるマイオカインを指標として、その血中濃度が高い場合は、肌状態が良いと推定される。
一方、イリシン、ＩＬ－７、ＩＬ－１β、ＭＣＰ１、ＣＸＣＬ１、及びＳＰＡＲＣから選択されるマイオカインを指標として、その血中濃度が低い場合は、肌状態が良いと推定される。
また、ＭＩＦ、ＣＸＣＬ５、及びＣＸＣＬ６から選択されるマイオカインを指標とするときは、その血中濃度が高い場合は肌状態のうち後述の肌荒れが良好であると推定され、その血中濃度が低い場合は後述の肌状態のうちシワ及び／又は色素沈着が良好であると推定される。
また、ＢＡＩＢＡを指標とするときは、その血中濃度が高い場合は肌状態のうち後述の色素沈着が良好であると推定され、その血中濃度が低い場合は後述の肌状態のうち肌荒れが良好であると推定される。
本発明において、マイオカインは一種又は二種以上のマイオカインを指標とすることができる。
Specifically selected from cathepsin B, IL-4, IL-6, IL-8, IL-10, IL-15, LIF, CX3CL1, GM-CSF, TNF-α, adiponectin, INF-γ, and BDNF As an index of myokines, it is presumed that the skin condition is good when its blood concentration is high.
On the other hand, when the blood concentration of myokines selected from irisin, IL-7, IL-1β, MCP1, CXCL1, and SPARC is low as an index, it is presumed that the skin condition is good.
In addition, when myokines selected from MIF, CXCL5, and CXCL6 are used as indicators, when the blood concentration is high, it is estimated that rough skin, which will be described later, is good among the skin conditions, and when the blood concentration is low. is presumed to have good wrinkles and/or pigmentation among the skin conditions described later.
In addition, when BAIBA is used as an index, when the blood concentration is high, it is estimated that the pigmentation described later among the skin conditions is good, and when the blood concentration is low, the skin is rough among the skin conditions described later. presumed to be good.
In the present invention, one or more types of myokines can be used as indicators for myokines.
本発明の鑑別法により推定される肌状態は、好ましくは、シワ、色素沈着、肌色、肌荒れ、及びハリ・弾力であり、通常には、上記肌状態の一種または二種以上である。なお、ここでいう肌の部位は顔面、四肢、頸部、胴部等特に限定されないが、通常は顔面の肌状態について鑑別を行う。以下に種々の肌状態と、それらを表すパラメータについて説明する。 The skin conditions estimated by the discrimination method of the present invention are preferably wrinkles, pigmentation, skin color, rough skin, and firmness/elasticity, and usually one or more of the above skin conditions. In addition, although the part of the skin referred to here is not particularly limited to the face, limbs, neck, body, etc., the skin condition of the face is usually discriminated. Various skin conditions and parameters representing them will be described below.
本明細書において「シワ」は、加齢シワや表情シワ等の皮溝の目立ちを示す概念であり、通常はシワの個数や任意の基準でスコア化した値で表される。
シワが少なかったり目立たないことは、肌表面の均一性が高く、なめらかで若々しい好ましい状態を示す。一方、シワが多かったり目立つことは、肌表面が不均一で、なめらかでなく、老いた印象を与え、良好とは認識されない状態を示す。なお、「シワ」とは、目視による認識の他、後述の解析プログラムにより認識されるものをいう。
シワの個数やスコアは、一般に、直接被験者の測定部位を観察してカウントする他、皮膚計測機器を用いて測定される。かかる皮膚計測機器としては例えば、ＶＩＳＩＡ－Ｅｖｏｌｕｔｉｏｎ（Ｃａｎｆｉｅｌｄ Ｓｃｉｅｎｔｉｆｉｃ Ｉｎｃ．）が例示でき、一定条件で撮影した写真に基づき、解析プログラムによりシワとして認識される数を計測したり、それに基づきスコア化する。
例えば、シワに係る肌状態が良好であるというのは、片方の頬の範囲（３０ｃｍ２）のシワ個数が前記計測機器で測定したときに９１個未満であることをいう、等と当てはめることができる。あるいは、シワに係る肌状態が良好であるというのは、測定対象者のシワ個数又はシワスコアは、４０～５０代女性１００名以上の標準パネラーにおいて取得したシワ個数の少ない方又はシワスコアの低い方からの順位付けに照らし合わせたときに、上位２５％以上、より好ましくは２０％以上に相当する等と当てはめることができる。
なお、測定部位は特に限定されないが、頬が好ましい。
As used herein, "wrinkles" is a concept that indicates conspicuousness of cutaneous sulci such as age-related wrinkles and facial wrinkles, and is usually represented by a value obtained by scoring the number of wrinkles or an arbitrary standard.
Few or inconspicuous wrinkles indicate a highly uniform skin surface, smooth and youthful desirable condition. On the other hand, many or conspicuous wrinkles indicate that the skin surface is uneven, not smooth, gives an aged impression, and is not recognized as good. The term "wrinkle" refers to not only visual recognition but also recognition by an analysis program to be described later.
The number and score of wrinkles are generally measured by directly observing and counting the measurement site of the subject, or by using a skin measuring instrument. An example of such a skin measurement device is VISIA-Evolution (Canfield Scientific Inc.), which measures the number of wrinkles recognized by an analysis program based on photographs taken under certain conditions, and scores them based thereon.
For example, a good skin condition related to wrinkles means that the number of wrinkles in the range (30 cm 2 ) of one cheek is less than 91 when measured with the above measuring device. can. Alternatively, the fact that the skin condition related to wrinkles is good means that the number of wrinkles or the wrinkle score of the person to be measured is obtained from a standard panel of 100 or more women in their 40s to 50s with a small number of wrinkles or a low wrinkle score. It can be applied that it corresponds to the top 25% or more, more preferably 20% or more, when compared with the ranking of .
The measurement site is not particularly limited, but cheeks are preferable.
本明細書において「色素沈着」は、メラニン色素が皮膚に沈着することにより生じるシミや肌の色ムラ等の状態を示す概念であり、通常はシミの個数や任意の基準でスコア化した値で表される。シミについては、メラニンシミと紫外線シミとを区別して表してもよい。
メラニンが目立たず、シミが少なかったり色ムラが小さいことは、美しく、若々しく、又は健康的で好ましい状態を示す。一方、メラニンが多いためにシミが多かったり色ムラが大きいことは、老いた印象を与えたり、良好とは認識されない状態を示す。なお、「色ムラ」とは、肌表面の色みの均一の程度をいう。
シミや色ムラ等の色素沈着パラメータは、一般に、直接被験者の測定部位を観察して評価する他、皮膚計測機器を用いて測定される。かかる皮膚計測機器としては例えば、ＶＩＳＩＡ－Ｅｖｏｌｕｔｉｏｎ（Ｃａｎｆｉｅｌｄ Ｓｃｉｅｎｔｉｆｉｃ Ｉｎｃ．）が例示でき、一定条件で撮影した写真に基づき、解析プログラムにより、メラニンシミ個数、
メラニンシミスコア、シミ個数、シミスコア、紫外線シミ個数、紫外線シミスコア、色ムラ指数、色ムラスコア等を測定し算出する。
また、分光測色計ＣＭ－２６００ｄ（コニカミノルタオプティクス）等の測色器を用いて、顔面とそれ以外の部位の肌色を測定しその差を算出して、色素沈着パラメータとしてもよい。例えば、顔面頬部と上腕内側との、ＲＧＢ、マンセル（明度、色相、彩度）、Ｌ＊ａ＊ｂ＊、ＸＹＺ、Ｌ＊Ｃ＊ｈ、ハンターＬａｂ等の表色系で表示される測色値の差やメラニンインデックス（ＭＩ）の差をパラメータとすることができ、特に上腕内側と顔面頬部のＭＩ差、又は上腕内側と顔面頬部のＬ＊差を好ましく用いることができる。
また、メラニンチェッカー（ポーラ化成工業株式会社）を用いて、角層メラニン量、角層メラニン均一性、及び角層メラニン面積等を測定し、その測定値やスコア化したものを色素沈着パラメータとしてもよい。
例えば、色素沈着に係る肌状態が良好であるというのは、片方の頬（３０ｃｍ２）の範囲のシミ個数が前記計測機器で測定したときに６０個未満であることをいう、色ムラスコアが８４１未満であることをいう、あるいは上腕内側と顔面頬部のＭＩ差が０．２４未満であることをいう、等と当てはめることができる。あるいは、色素沈着に係る肌状態が良好であるというのは、測定対象者のシミや色ムラに係るパラメータは、４０～５０代女性１００名以上の標準パネラーにおいて取得したパラメータの良い方からの順位付けに照らし合わせたときに、上位２５％以上、より好ましくは２０％以上に相当する等と当てはめることができる。
なお、測定部位は特に限定されないが、頬が好ましい。
As used herein, “pigmentation” is a concept that indicates a state such as spots and uneven skin color caused by the deposition of melanin pigment on the skin, and is usually a scored value based on the number of spots or an arbitrary standard. expressed. As for blemishes, melanin blemishes and ultraviolet blemishes may be distinguished from each other.
Inconspicuous melanin, less blemishes, and less color unevenness indicate a beautiful, youthful, or healthy, and desirable state. On the other hand, a large amount of melanin resulting in a large number of blemishes and large unevenness in color gives an aged impression and indicates a state that is not recognized as good. In addition, "unevenness of color" means the degree of uniformity of the color of the skin surface.
Pigmentation parameters such as blemishes and color unevenness are generally evaluated by directly observing the subject's measurement site, and are also measured using a skin measuring instrument. Examples of such skin measurement equipment include VISIA-Evolution (Canfield Scientific Inc.), and based on photographs taken under certain conditions, the number of melanin spots,
The melanin blemish score, the number of blemishes, the blemish score, the number of ultraviolet blemishes, the ultraviolet blemish score, the color unevenness index, the color unevenness score, etc. are measured and calculated.
Alternatively, a colorimeter such as a spectrophotometer CM-2600d (Konica Minolta Optics) may be used to measure the skin color of the face and other parts, calculate the difference, and use it as a pigmentation parameter. For example, measurements displayed in a color system such as RGB, Munsell (brightness, hue, saturation), L*a*b*, XYZ, L*C*h, Hunter Lab, etc., between the cheeks of the face and the inner side of the upper arm A difference in color value or a difference in melanin index (MI) can be used as a parameter, and in particular, the MI difference between the inner side of the upper arm and the cheek of the face or the L* difference between the inner side of the upper arm and the cheek of the face can be preferably used.
In addition, using a melanin checker (POLA CHEMICAL INDUSTRIES, INC.), the amount of stratum corneum melanin, the stratum corneum melanin uniformity, the stratum corneum melanin area, etc. are measured, and the measured values and scored values are used as pigmentation parameters. good.
For example, a good skin condition related to pigmentation means that the number of blemishes in the range of one cheek (30 cm 2 ) is less than 60 when measured with the above-mentioned measuring device, and the color unevenness score is 841. or less than 0.24 between the inner upper arm and the face cheek. Alternatively, the fact that the skin condition related to pigmentation is good means that the parameters related to spots and color unevenness of the measurement subject are the parameters obtained from a standard panel of 100 or more women in their 40s and 50s. It can be applied, for example, to correspond to the top 25% or more, more preferably 20% or more, when compared to the ranking.
The measurement site is not particularly limited, but cheeks are preferable.
「肌色」は、肌の色味や明るさによって、若々しさや健康的な印象を左右する肌の状態の要素である。一般には、分光測色計や色彩色差計などで測定され、かかる測定機器としては、例えば分光測色計ＣＭ－２６００ｄ（コニカミノルタオプティクス）等が好ましく挙げられる。肌色は、例えばＲＧＢ、マンセル（明度、色相、彩度）、Ｌ＊ａ＊ｂ＊、ＸＹＺ、Ｌ＊Ｃ＊ｈ、ハンターＬａｂ等の表色系で表示でき、これらのうち特にマンセルバリュー（明度）、マンセルクロマ（彩度）、ｂ＊、又はＬ＊の測定値で表すことが好ましい。また、肌の色味には毛細血管の構造や分布が大きく影響するため、肌表面から観察されるヘモグロビンに係る指数や任意の基準でスコア化した値で表示することもできる。
肌色が明るい又は白側に近い色味であったりヘモグロビンが適度に少ないことは、美しく、若々しく、又は健康的で好ましい状態を示す。一方、肌色の明るさが乏しく赤みが強かったり、ヘモグロビンが過度に多いことは、老いた印象を与えたり、良好とは認識されない状態を示す。
例えば、肌色が良好であるというのは、頬のマンセルバリュー値が５．９以上であることをいう、マンセルクロマ値が３．８以上であることをいう、あるいはヘモグロビンスコアが３２未満であることをいう、等と当てはめることができる。あるいは、肌色が良好であるというのは、測定対象者の肌色やヘモグロビンに係るパラメータは、４０～５０代女性１００名以上の標準パネラーにおいて取得したパラメータの良い方からの順位付けに照らし合わせたときに、上位２５％以上、より好ましくは２０％以上に相当する等と当てはめることができる。
なお、測定部位は特に限定されないが、頬が好ましい。
“Skin color” is an element of skin condition that influences impressions of youthfulness and health depending on the tone and brightness of the skin. In general, it is measured with a spectrophotometer, a color difference meter, or the like, and a preferable example of such a measuring instrument is a spectrophotometer CM-2600d (Konica Minolta Optics). Skin color can be displayed in color systems such as RGB, Munsell (brightness, hue, saturation), L*a*b*, XYZ, L*C*h, Hunter Lab. ), Munsell chroma (chroma), b*, or L* measurements. In addition, since the structure and distribution of capillaries greatly affect the color tone of the skin, it is possible to display an index related to hemoglobin observed from the surface of the skin or a scored value based on an arbitrary standard.
A light or white skin color or moderately low hemoglobin indicates a beautiful, youthful, or healthy, and desirable state. On the other hand, skin with poor brightness and strong redness or excessive hemoglobin gives an aged impression and indicates a state that is not recognized as good.
For example, a good complexion means that the cheek Munsell value value is 5.9 or more, the Munsell chroma value is 3.8 or more, or the hemoglobin score is less than 32. , etc. can be applied. Alternatively, when the skin color is good, the parameters related to the skin color and hemoglobin of the person being measured are compared with the ranking of the best parameters obtained from a standard panel of 100 or more women in their 40s and 50s. to the top 25% or more, more preferably 20% or more.
The measurement site is not particularly limited, but cheeks are preferable.
「肌荒れ」は、角層バリア機能が低下して、肌の水分量と皮脂量のバランスが崩れたり、ニキビなどの炎症が生じたりして、滑らかさやキメが損なわれた程度を表す、肌の状態の要素である。肌荒れの程度が小さいことは、美しく、若々しく、又は健康的で好ましい状態を示す。一方、肌荒れの程度が大きいことは、老いた印象を与えたり、良好とは認識されない状態を示す。肌荒れは、通常は、角層水分量、経皮水分蒸散量（ＴＥＷＬ）、角層規則性、皮脂量、ポルフィリン個数等を定法にて測定した値やそれを任意の基準でスコア化した値を表される。なお、ポルフィリンはニキビの原因となるアクネ菌の代謝物であり、該菌の存在を示す。
例えば、肌荒れが良好であるというのは、頬の角層水分量が１６３以上であることをいう、ＴＥＷＬが９．３未満であることをいう、あるいは皮脂量が９未満であることをいう、等と当てはめることができる。あるいは、肌荒れが良好であるというのは、測定対象者の角層規則性のスコア等の肌荒れに係るパラメータは、４０～５０代女性１００名以上の標準パネラーにおいて取得したパラメータの良い方からの順位付けに照らし合わせたときに、上位２５％以上、より好ましくは２０％以上に相当する等と当てはめることができる。
なお、測定部位は特に限定されないが、頬が好ましい。
“Rough skin” refers to the extent to which the barrier function of the stratum corneum has deteriorated, resulting in an imbalance between the amount of moisture and sebum in the skin, inflammation such as acne, etc., resulting in loss of smoothness and texture. It is an element of state. A small degree of rough skin indicates a beautiful, youthful, or healthy and desirable condition. On the other hand, a large degree of rough skin gives an aged impression or indicates a state that is not recognized as good. Rough skin is usually measured by standard methods for stratum corneum water content, transepidermal water loss (TEWL), stratum corneum regularity, sebum content, number of porphyrins, etc., or scored based on arbitrary criteria. expressed. Porphyrin is a metabolite of P. acnes, which causes acne, and indicates the presence of this bacterium.
For example, good rough skin means that the moisture content of the horny layer of the cheek is 163 or more, that the TEWL is less than 9.3, or that the sebum content is less than 9. etc. can be applied. Alternatively, the fact that rough skin is good means that the parameters related to rough skin such as the score of the regularity of the stratum corneum of the measurement subject are ranked from the better parameters obtained from a standard panel of 100 or more women in their 40s and 50s. It can be applied, for example, to correspond to the top 25% or more, more preferably 20% or more, when compared to the ranking.
The measurement site is not particularly limited, but cheeks are preferable.
「ハリ・弾力」は、肌が水平方向または垂直方向に加えられた力に対して押し返す性質、あるいは変形するがその力が除かれれば元に戻ろうとする（復元する）性質である。例えば、皮膚の粘弾物性で表される。例えば、Ｃｕｔｏｍｅｔｅｒ ＭＰＡ５８０（Ｃｏｕｒａｇｅ ＋ Ｋｈａｚａｋａ Ｅｌｅｃｔｒｏｎｉｃ ＧｍｂＨ）等の測定機器を用いて、粘弾性や純弾性等を測定した値やそれを任意の基準でスコア化した値をハリ・弾力のパラメータとすることができる。
ハリ・弾力が大きいと、真皮のクッションとしての機能が高く、弾力性・伸縮性に富むため、その肌は若々しく、又は健康的で好ましい状態を示す。一方、ハリ・弾力が小さいと、真皮の弾力性が乏しいため、その肌は応力に対して復元できず、老いた印象を与えたり、良好とは認識されない状態を示す。
例えば、ハリ・弾力が良好であるというのは、頬の純弾性が０．３４以上であることをいう等と当てはめることができる。あるいは、ハリ・弾力が良好であるというのは、測定対象者の粘弾性値やスコア等のハリ・弾力パラメータは、４０～５０代女性１００名以上の標準パネラーにおいて取得したパラメータの良い方からの順位付けに照らし合わせたときに、上位２５％以上、より好ましくは２０％以上に相当する等と当てはめることができる。
なお、測定部位は特に限定されないが、頬が好ましい。
“Firmness/elasticity” refers to the property of the skin to push back against force applied in the horizontal or vertical direction, or the property of deforming but trying to return (restore) when the force is removed. For example, it is represented by the viscoelastic properties of the skin. For example, using a measuring instrument such as Cutometer MPA580 (Courage + Khazaka Electronic GmbH), a value obtained by measuring viscoelasticity, pure elasticity, etc., or a value obtained by scoring it based on an arbitrary standard can be used as a parameter of firmness / elasticity. can.
When the firmness/elasticity is high, the function of the dermis as a cushion is high, and the skin is rich in elasticity/stretchability, so that the skin appears youthful or healthy and preferable. On the other hand, if the firmness/elasticity is low, the elasticity of the dermis is so poor that the skin cannot restore itself to stress, giving an aged impression or not being recognized as good.
For example, good firmness/elasticity means that the pure elasticity of the cheeks is 0.34 or more. Alternatively, the firmness and elasticity are good because the firmness and elasticity parameters such as the viscoelasticity value and score of the measurement subject are obtained from a standard panel of 100 or more women in their 40s and 50s from the better parameters. It can be applied to correspond to the top 25% or more, more preferably 20% or more when compared to the ranking.
The measurement site is not particularly limited, but cheeks are preferable.
本発明の鑑別法では、測定により得た血中マイオカイン濃度を多変量解析によって得られた推定式に当てはめることにより、肌状態を表すパラメータを導くことによって解析を行うことが好ましい。前記推定式は、多変量解析のソフトウェアを利用して、実測した血中マイオカイン濃度と肌状態パラメータとの相関分析及び回帰分析を行って作成できる。そのようなソフトウェアとして、装置に付属したソフトウェア、ＳＰＳＳ社やＳＡＳ社等の市販されているソフトウェアあるいはフリーソフトなどを用いることができ、特に制限されない。
また、推定式を作成するに際して測定標準となるパネラーは、特に限定されないが、好ましくは３０名以上、より好ましくは５０名以上、さらに好ましくは１００名以上であることが、解析の正確性を確保するため好ましい。また、年齢は２０～６０代というように広範囲に偏りなく分布させることが好ましく、必要によっては年齢の要素を加味した推定式を作成してもよい。また、性別もそろえることが好ましい。
In the discrimination method of the present invention, it is preferable to apply the blood myokine concentration obtained by measurement to an estimation formula obtained by multivariate analysis, thereby deriving a parameter representing the skin condition for analysis. The estimation formula can be created by performing correlation analysis and regression analysis between actually measured blood myokine concentrations and skin condition parameters using multivariate analysis software. As such software, software attached to the device, software commercially available from SPSS, SAS, etc., free software, or the like can be used, and is not particularly limited.
In addition, the panelists that serve as the measurement standard when creating the estimation formula are not particularly limited, but are preferably 30 or more, more preferably 50 or more, and still more preferably 100 or more to ensure the accuracy of the analysis. preferred because In addition, it is preferable to distribute the age evenly over a wide range, such as the 20s to 60s, and if necessary, an estimation formula may be created in consideration of the age factor. In addition, it is preferable to match the gender.
本発明の鑑別法の対象は、特に限定されず、人一般とすることができる。また、対象の性別は、特に限定されないが、美容カウンセリングの需要の観点から好ましくは女性である。また、対象の年齢は、特に限定されず、例えば２０～６０代とすることができる。 The object of the identification method of the present invention is not particularly limited, and can be any person in general. In addition, the sex of the subject is not particularly limited, but from the viewpoint of demand for beauty counseling, it is preferably female. Also, the age of the subject is not particularly limited, and can be, for example, 20s to 60s.
以下、本発明を実施例により更に詳細に説明するが、本発明は、その要旨を超えない限り、以下の実施例に限定されるものではない。 EXAMPLES Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples as long as the gist thereof is not exceeded.
＜実施例１＞血中マイオカイン濃度と肌状態との相関解析
（１）血中マイオカイン濃度の測定
試験参加の同意を得た４０代及び５０代の日本人女性２８名から、全血を採取して血清を得、各種ＥＬＩＳＡキットおよびＬＣ－ＭＳ（日本ウォーターズ）により前記血清中の各種マイオカイン濃度を測定した。
<Example 1> Correlation analysis between blood myokine concentration and skin condition (1) Measurement of blood myokine concentration Whole blood was collected from 28 Japanese women in their 40s and 50s who gave consent to participate in the study. Serum was obtained from the mice, and various myokine concentrations in the serum were measured using various ELISA kits and LC-MS (Nippon Waters).
（２）肌状態の測定
（１）と同じ被験者について、下記の手順で種々の肌状態パラメータをそれぞれ測定した。
分光測色計ＣＭ－２６００ｄ（コニカミノルタオプティクス）を用いて、測定点４か所の色を、マンセル及びＬ＊ａ＊ｂ＊の表色系で各３回ずつ測定し、各平均値及びメラニンインデックス（ＭＩ）を算出した。４か所の測定点は、左目尻から垂直方向に下ろした線と鼻尖点から水平方向に延ばした線との交点、右目尻から垂直方向に下ろした線と鼻尖点から水平方向に延ばした線との交点、左目尻から垂直方向に下ろした線と左口角から水平方向に延ばした線との交点、及び右目尻から垂直方向に下ろした線と左口角から水平方向に延ばした線との交点、とした。なお、測定点が色素沈着部位である場合は、当該部位を外したすぐ右隣を測定部位とした。
(2) Measurement of skin condition For the same subjects as in (1), various skin condition parameters were measured according to the following procedure.
Using a spectrophotometer CM-2600d (Konica Minolta Optics), the color at four measurement points was measured three times each in the Munsell and L*a*b* color systems, and each average value and melanin Index (MI) was calculated. The four measurement points are the intersection of a line drawn vertically from the outer corner of the left eye and a line drawn horizontally from the tip of the nose, a line drawn vertically from the corner of the right eye and a line drawn horizontally from the tip of the nose. , the intersection of the line drawn vertically from the corner of the left eye and the line drawn horizontally from the corner of the left mouth, and the intersection of the line drawn vertically from the corner of the right eye and the line drawn horizontally from the corner of the left mouth , and. When the measurement point was a pigmentation site, the site immediately to the right of the removed site was used as the measurement site.
皮膚計測機器ＶＩＳＩＡ－Ｅｖｏｌｕｔｉｏｎ（Ｃａｎｆｉｅｌｄ Ｓｃｉｅｎｔｉｆｉｃ Ｉｎｃ．）を用いて、被験者の顔写真を撮影した。被験者はグレーのケープを着用し、目を閉じた状態で、画像補正用カラーチャート（ＣＡＳＭＡＴＣＨ）と共に撮影した。撮影モードは標準光、ＵＶ、直交偏波（ｃｒｏｓｓ－ｐｏｌａｒｉｚａｔｉｏｎ）の３種とし、各モードで正面左右１枚ずつ撮影した。得られた写真に基づいて、前記機器の解析プログラムにより被験者の両頬の、メラニン個数、毛穴個数、ヘモグロビン指数、シミ個数、色ムラ指数、紫外線シミ個数、シワ個数、ポルフィリン個数、メラニンスコア、毛穴スコア、ヘモグロビンスコア、シミスコア、色ムラスコア、紫外線シミスコア、シワスコア、及びポルフィリンスコアを算出した。 Using a skin measuring device VISIA-Evolution (Canfield Scientific Inc.), the subject's face was photographed. The subject wore a gray cape and had his eyes closed, and was photographed together with a color chart for image correction (CASMATCH). There were three photographing modes, standard light, UV, and cross-polarization, and one front left and right photograph was taken in each mode. Based on the obtained photographs, the number of melanin, the number of pores, the hemoglobin index, the number of blemishes, the uneven color index, the number of ultraviolet blemishes, the number of wrinkles, the number of porphyrins, the number of melanin, the number of pores, and the number of pores on both cheeks of the subject were determined based on the obtained photographs. A score, a hemoglobin score, a blemish score, an uneven color score, an ultraviolet blemish score, a wrinkle score, and a porphyrin score were calculated.
ＳＫＩＣＯＮ－２００ＥＸ（株式会社ヤヨイ）を用いて、頬の角層水分量を測定した。
ＶＡＰＯ ＳＣＡＮ ＡＳ－ＶＴ１００ＲＳ（株式会社アサヒテクノラボ）を用いて、頬の経表皮水分蒸散量（ＴＥＷＬ）を測定した。
Ｃｕｔｏｍｅｔｅｒ ＭＰＡ５８０（Ｃｏｕｒａｇｅ ＋ Ｋｈａｚａｋａ Ｅｌｅｃｔｒｏｎｉｃ ＧｍｂＨ）を用いて、頬の純弾性、及び粘弾性を測定した。
Ｓｅｂｕｍｅｔｅｒ ＳＭ８１０（Ｃｏｕｒａｇｅ ＆ Ｋｈａｚａｋａ Ｅｌｅｃｔｒｏｎｉｃ ＧｍｂＨ）を用いて、頬の皮脂量を測定した。
角層・メラニンチェッカー（ポーラ化成工業株式会社）を用いて、頬の角層の剥がれ具合（ＴＡ）、角層の規則性、角層細胞の脱核具合、角層メラニン量、角層メラニン均一性、及び角層メラニン面積を測定した。
Using SKICON-200EX (Yayoi Co., Ltd.), the moisture content of the horny layer of the cheek was measured.
A VAPO SCAN AS-VT100RS (Asahi Techno Lab Co., Ltd.) was used to measure the transepidermal water loss (TEWL) of the cheeks.
Pure elasticity and viscoelasticity of the cheeks were measured using a Cutometer MPA580 (Courage + Khazaka Electronic GmbH).
A Sebumeter SM810 (Courage & Khazaka Electronic GmbH) was used to measure the amount of sebum on the cheeks.
Using a stratum corneum/melanin checker (POLA CHEMICAL INDUSTRIES, INC.), peeling of stratum corneum on cheeks (TA), regularity of stratum corneum, degree of denucleation of stratum corneum cells, amount of melanin in stratum corneum, uniformity of melanin in stratum corneum sex and stratum corneum melanin area were measured.
（３）解析
上記測定した血中マイオカイン濃度と種々の肌状態パラメータとを用いて、ＪＭＰ ｖｅｒ.１３．０（ＳＡＳ）を使用して、相関分析及び回帰分析を行った。その結果、血中マイオカイン濃度と肌状態との間に正又は負の有意な相関関係（ｐ＜０．０５）が認められた。血中濃度が低いと肌状態が良好であるマイオカインを表１に、血中濃度が高いと肌状態が良好であるマイオカインを表２にそれぞれ掲載する。これらの結果から、血中マイオカイン濃度を指標として肌のシワ、色素沈着、肌色、肌荒れ、及びハリ・弾力に関する肌状態を推定できることがわかる。
(3) Analysis Correlation analysis and regression analysis were performed using JMP ver.13.0 (SAS) using the blood myokine concentrations measured above and various skin condition parameters. As a result, a significant positive or negative correlation (p<0.05) was observed between blood myokine concentration and skin condition. Table 1 lists the myokines that improve the skin condition when the blood concentration is low, and Table 2 lists the myokines that improve the skin condition when the blood concentration is high. From these results, it can be seen that skin conditions such as wrinkles, pigmentation, skin color, rough skin, and firmness/elasticity can be estimated using the blood myokine concentration as an index.
本発明により、簡便かつ高精度に、肌状態を推定することができる。これにより、肌の手入れや化粧方法を検討・選択・決定する際に有用な情報を得ることができ、該情報を肌の手入れや化粧方法に関するカウンセリングにも利用できるため、産業上非常に有用である。 According to the present invention, the skin condition can be estimated simply and with high accuracy. As a result, useful information can be obtained when examining, selecting, and determining skin care and makeup methods, and the information can also be used for counseling regarding skin care and makeup methods, making it extremely useful industrially. be.
Claims (9)
血中マイオカイン濃度が予め用意した基準に対して高い場合に肌状態が良いと推定する、鑑別法。 A skin condition discrimination method performed for cosmetic purposes, characterized in that the skin condition is estimated using the blood myokine concentration as an index,
A discrimination method in which the skin condition is estimated to be good when the blood myokine concentration is higher than the standard prepared in advance.
前記マイオカインが、イリシン、ＩＬ－７、ＩＬ－１β、ＭＣＰ１、及びＳＰＡＲＣから選択され、
血中マイオカイン濃度が予め用意した基準に対して低い場合に肌状態が良いと推定する、鑑別法。 A skin condition discrimination method performed for cosmetic purposes, characterized in that the skin condition is estimated using the blood myokine concentration as an index,
the myokine is selected from irisin, IL-7, IL-1β, MCP1, and SPARC;
A discrimination method in which the skin condition is estimated to be good when the blood myokine concentration is lower than the standard prepared in advance.
前記マイオカインが、ＣＸＣＬ１であり、
血中マイオカイン濃度が予め用意した基準に対して低い場合に、色素沈着、肌色、及びハリ・弾力から選択される肌状態が良いと推定される、鑑別法。 A skin condition discrimination method performed for cosmetic purposes, characterized in that the skin condition is estimated using the blood myokine concentration as an index,
the myokine is CXCL1,
A discrimination method in which when the blood myokine concentration is low relative to a standard prepared in advance, the skin condition selected from pigmentation, skin color, and firmness/elasticity is estimated to be good.
前記マイオカインが、ＭＩＦ、及びＣＸＣＬ５から選択され、
血中マイオカイン濃度が予め用意した基準に対して高い場合に肌荒れの肌状態が良いと推定する、鑑別法。 A skin condition discrimination method performed for cosmetic purposes, characterized in that the skin condition is estimated using the blood myokine concentration as an index,
the myokine is selected from MIF and CXCL5;
A discrimination method in which a rough skin condition is estimated to be good when the blood myokine concentration is higher than a standard prepared in advance.
前記マイオカインが、ＭＩＦ、ＣＸＣＬ５、及びＣＸＣＬ６から選択され、
血中マイオカイン濃度が予め用意した基準に対して低い場合に、シワ及び色素沈着から選択される肌状態が良いと推定する、鑑別法。 A skin condition discrimination method performed for cosmetic purposes, characterized in that the skin condition is estimated using the blood myokine concentration as an index,
the myokine is selected from MIF, CXCL5, and CXCL6;
A discrimination method in which when the blood myokine concentration is low relative to a standard prepared in advance, the skin condition selected from wrinkles and pigmentation is estimated to be good.
前記マイオカインが、ＢＡＩＢＡであり、
血中マイオカイン濃度が予め用意した基準に対して高い場合に、色素沈着の肌状態が良いと推定し、
血中マイオカイン濃度が予め用意した基準に対して低い場合に、肌荒れの肌状態が良いと推定する、鑑別法。 A skin condition discrimination method performed for cosmetic purposes, characterized in that the skin condition is estimated using the blood myokine concentration as an index,
the myokine is BAIBA,
When the blood myokine concentration is higher than the standard prepared in advance, it is estimated that the skin condition of pigmentation is good,
A discrimination method in which a rough skin condition is estimated to be good when the blood myokine concentration is lower than a standard prepared in advance .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018172460A JP7259169B2 (en) | 2018-09-14 | 2018-09-14 | Differentiation method of skin condition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018172460A JP7259169B2 (en) | 2018-09-14 | 2018-09-14 | Differentiation method of skin condition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020046200A JP2020046200A (en) | 2020-03-26 |
| JP7259169B2 true JP7259169B2 (en) | 2023-04-18 |
Family
ID=69901349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018172460A Active JP7259169B2 (en) | 2018-09-14 | 2018-09-14 | Differentiation method of skin condition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7259169B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022030300A1 (en) * | 2020-08-03 | 2022-02-10 | 株式会社村田製作所 | Skin condition inference method, skin condition inference device, and skin condition inference system |
| JP7834457B2 (en) * | 2021-11-17 | 2026-03-24 | ポーラ化成工業株式会社 | IL-1α expression inhibitor |
| CN115154610B (en) * | 2022-08-06 | 2023-09-15 | 中南大学湘雅三医院 | Application of CX3CL1 enhancer or inhibitor in preparation of medicines for treating pigmentation-abnormal skin diseases |
| CN120265981A (en) * | 2022-12-28 | 2025-07-04 | 株式会社资生堂 | Skin condition estimation method, skin condition estimation device, and program |
| JP2025030226A (en) * | 2023-08-23 | 2025-03-07 | 株式会社 資生堂 | Skin condition estimation method, skin condition estimation device, skin condition estimation system, and program |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008247905A (en) | 2007-03-20 | 2008-10-16 | Johnson & Johnson Consumer France Sas | COMPOSITION CONTAINING RETINOID AND beta-AMINOISOBUTYRIC ACID DERIVATIVE |
| JP2009249369A (en) | 2008-04-10 | 2009-10-29 | Fancl Corp | Suppressant for dermal pigmentation |
| JP2011185923A (en) | 2010-02-09 | 2011-09-22 | Pola Chemical Industries Inc | Evaluation method of skin condition |
| WO2014208645A1 (en) | 2013-06-28 | 2014-12-31 | 中外製薬株式会社 | Method for predicting response of patient with pruiritic disease to il-31 antagonist therapy |
| JP2019147777A (en) | 2018-02-28 | 2019-09-05 | 株式会社ファンケル | Myokine production promoting composition |
-
2018
- 2018-09-14 JP JP2018172460A patent/JP7259169B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008247905A (en) | 2007-03-20 | 2008-10-16 | Johnson & Johnson Consumer France Sas | COMPOSITION CONTAINING RETINOID AND beta-AMINOISOBUTYRIC ACID DERIVATIVE |
| JP2009249369A (en) | 2008-04-10 | 2009-10-29 | Fancl Corp | Suppressant for dermal pigmentation |
| JP2011185923A (en) | 2010-02-09 | 2011-09-22 | Pola Chemical Industries Inc | Evaluation method of skin condition |
| WO2014208645A1 (en) | 2013-06-28 | 2014-12-31 | 中外製薬株式会社 | Method for predicting response of patient with pruiritic disease to il-31 antagonist therapy |
| JP2019147777A (en) | 2018-02-28 | 2019-09-05 | 株式会社ファンケル | Myokine production promoting composition |
Non-Patent Citations (1)
| Title |
|---|
| 小川真輝ほか，１時間のランニングは血中CXCL-1レベルを上昇させる，第４９回日本理学療法学術大会予稿集，日本，2014年，1552 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020046200A (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7259169B2 (en) | Differentiation method of skin condition | |
| US20150099947A1 (en) | Skin youthfulness index, methods and applications thereof | |
| JP2012245356A (en) | Method for characterizing tone of skin and integument | |
| US20080304736A1 (en) | Method of estimating a visual evaluation value of skin beauty | |
| KR20110083615A (en) | Objective Models, Methods, and Uses of Apparent Ages | |
| JP7639201B2 (en) | Method for predicting hair and facial characteristics using scalp stratum corneum cell characteristics | |
| JP4489764B2 (en) | How to measure the effectiveness of a skin care program | |
| US20040201694A1 (en) | Noninvasive methods and apparatus for monitoring at least one hair characteristic | |
| JP6530703B2 (en) | Skin condition evaluation method | |
| JP5635762B2 (en) | Method for calculating nipple shape or collagen-like structure | |
| JP2002017689A (en) | Method of measuring and evaluating quality sensation of skin, and use of compound showing effectiveness by this method | |
| CN104970797A (en) | Skin classification method, cosmetics recommendation method and skin classification card | |
| CN115699113A (en) | Intelligent system for skin testing, custom formulation and cosmetic production | |
| JP7442960B2 (en) | How to differentiate skin conditions | |
| JP7307544B2 (en) | Method for evaluating skin clarity | |
| JPH1128193A (en) | How to display skin condition | |
| CN116681661A (en) | A method and application for evaluating the degree of improvement of human facial pores | |
| JP2025067291A (en) | Skin age estimation method by tokyo university-method makeup theory | |
| JP2016193175A (en) | Extraction method of determination part for apparent face impression, extraction method of determining factor for apparent face impression, and differentiation method for apparent face impression | |
| CN116077030A (en) | Skin evaluation method based on skin component volume content | |
| JP2020022742A (en) | Method for improving skin condition | |
| CN114764731A (en) | Skin care recommendation method and system based on skin image detection | |
| JP7852179B2 (en) | Skin physiological index estimation method | |
| JP2021112407A (en) | Apparent age estimating method | |
| JP2024163871A (en) | How to assess the effect of face lifting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210817 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220913 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230106 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230307 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230310 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7259169 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |